Cohen & SteersGenworth

Cohen & Steers vs Genworth

Specialist real estate investment manager with diversified funds vs Mortgage insurance and legacy long term care provider. Which is the better buy for your portfolio in June 2026? Plain-English answer below.

Cohen & Steers is a specialized asset manager focused exclusively on real assets like REITs, infrastructure, and commodities, serving institutional and wealth management clients who want inflation-sen...

Investment Analysis

Pros

  • Cohen & Steers specialises in real estate securities and REITs, benefiting from sustained investor demand for listed alternatives and diversification.
  • Recent financial results exceeded analyst expectations, with both earnings and revenue surpassing forecasts, reflecting operational strength and effective management.
  • Analyst consensus acknowledges upward revisions to earnings estimates through 2026, suggesting positive momentum and potential for continued outperformance.

Considerations

  • Assets under management have declined year-over-year and remain significantly below previous peaks, indicating potential challenges in retaining or growing client funds.
  • The stock trades at a substantial premium to Morningstar’s fair value estimate, which may limit near-term upside and increase valuation risk.
  • Heavy reliance on real estate and listed alternatives exposes the firm to sector-specific volatility and potential underperformance during market downturns.

Pros

  • Genworth maintains a leading position in mortgage insurance and long-term care insurance, sectors with high barriers to entry and recurring revenue potential.
  • The company has made progress in deleveraging its balance sheet, improving financial flexibility and reducing interest expense in recent periods.
  • Ongoing efforts to optimise its legacy long-term care business could unlock value if successful, providing a potential catalyst for share price appreciation.

Considerations

  • Genworth’s long-term care insurance portfolio continues to face significant reserve adequacy and claims cost pressures, creating uncertainty around future profitability.
  • Regulatory scrutiny remains elevated for insurers in the long-term care and mortgage sectors, potentially limiting operational flexibility and increasing compliance costs.
  • The company’s growth prospects are constrained by intense competition in core markets, with limited near-term catalysts for material earnings acceleration.

Buy CNS or GNW in Nemo

Nemo Logo Fade
🆓

Zero Commission

Trade stocks, ETFs, and more with zero commission. Keep more of your returns.

🔒

Trusted & Regulated

Part of Exinity Group 2015, serving over a million customers globally.

💰

6% Interest on Cash

Earn 6% AER on uninvested cash with daily interest payments.

Frequently asked questions

CNS
CNS$77.49
vs
GNW
GNW$9.47
Buy CNS